Why BioVie (BIVI) Stock Is Down Over 50% Today
Why BioVie (BIVI) Stock Is Down Over 50% Today
BioVie Inc (NASDAQ:BIVI) shares are trading lower by 56.1% to $1.23 during Tuesday's session after the company announced it raised $3 million through a secondary offering of 1.96 million shares at $1.53 per share.
BioVie公司(纳斯达克股票代码:BIVI)股价在周二交易中下跌了56.1%,跌至1.23美元,此前该公司宣布通过次级发行196万股股票以每股1.53美元的价格筹集了300万美元。
What To Know: BioVie announced the pricing of a public offering consisting of 1,960,800 shares of its common stock (or pre-funded warrants) and accompanying warrants to purchase the same number of shares. The combined offering price is $1.53 per share or warrant, with an exercise price of $1.53 per share, exercisable immediately for five years.
需要了解的是:BioVie宣布定价公开发行1960800股普通股(或预先融资认股权),并附带购买相同数量股票的认股权。合并发行价格为每股或认股权1.53美元,行权价为每股1.53美元,可立即行使并有效期为五年。
The company expects to raise approximately $3 million from the offering, before fees and expenses, and plans to use the proceeds for working capital and general corporate purposes.
该公司预计将从该次发行中筹集约300万美元(扣除费用和开支),并计划将所得款项用于营运资金和一般企业用途。
The clinical-stage company anticipates that the offering will close on September 25, with ThinkEquity as the sole placement agent.
这家处于临床阶段的公司预计该发行将于9月25日结束,ThinkEquity担任唯一的配售代理。
Read Also: Chinese Stocks Jump As Central Bank Unveils Major Stimulus To Spur Economy: 'A Step In The Right Direction'
阅读更多:随着央行推出重大刺激措施刺激经济,中国股市大幅上涨:“迈向正确方向的一步”
Should I Sell My BIVI Stock?
我应该卖出我的BIVI股票吗?
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
卖出或持有股票很大程度上取决于投资者的策略和风险承受能力。短期交易者可能会出售表现优异的股票以锁定资本收益,而长期投资者可能会在期待股价进一步增长的动荡中保持持有。
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
同样,愿意将损失最小化的交易者可能会出售下跌一定百分比的股票,而长期投资者则可能会将其视为以折扣价买入更多股票的机会。
Shares of BioVie have lost 96.43% year to date. This compares to the average annual return of -66.09%, meaning the stock has underperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.
biovie股票今年迄今已经下跌了96.43%。这与平均年回报率-66.09%相比,意味着该股表现低于其历史平均水平。投资者可以将股票的走势与历史表现进行比较,以判断这是否是正常波动还是潜在的交易机会。
For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
欲获取分析工具、图表数据和独家股票新闻,请登录Benzinga PRO。现在免费试用。